ELON’s Medical Masterpiece: Private Market Spotlight: NEURALINK

G.L.A. INVEST RESEARCH | Private Market Spotlight

Elon’s Medical Masterpiece— Neuralink Corp.

“The mind is the last frontier — and Neuralink is building the bridge.”
— G.L.A. Invest Research

Executive Overview

Neuralink Corporation is not a speculative moonshot. It is a fully operational, FDA-recognized neurotechnology company building the most consequential medical device of the 21st century — a brain-computer interface (BCI) that allows the human brain to communicate directly with digital and physical systems. Founded in 2016 by Elon Musk alongside a team of world-class neuroscientists and engineers, Neuralink has evolved from a stealth-mode startup into a clinical-stage company with human participants on multiple continents, three FDA Breakthrough Device Designations, and a valuation that has surged from under $600 million to over $9 billion in under a decade.

For LPs of the AMP Growth Collective 2, access is available at $53 per share — a dramatic discount to where secondary shares are trading elsewhere. This report is our deep-dive into why G.L.A. Invest believes Neuralink represents one of the most asymmetric return opportunities in the private markets today.

Company History & Founding

Neuralink was founded in 2016 by Elon Musk and eight scientists and engineers — including neuroscientists, biochemists, and robotics experts — assembled after Musk met with over 1,000 potential candidates to build the ideal team. The founding group brought expertise across neuroscience, microscale electronics, and biomedical engineering. The company first publicly reported its existence in March 2017.[^2][^1]

The company’s core mission from day one has been dual-pronged: first, create implantable devices to treat serious neurological disorders; second, unlock long-term human cognitive enhancement and AI symbiosis. Musk’s driving thesis was that humanity needed a “third layer” to the brain — a digital cortex — to remain relevant in a world increasingly dominated by artificial intelligence.[^5]

Founding Team: Elon Musk, Dongjin “DJ” Seo (now President & CEO), Max Hodak, Benjamin Rapoport, Paul Merolla, Philip Sabes, Tim Gardner, Tim Hanson, and Vanessa Tolosa.[^2]

Early Development Timeline

The Technology: What Is Neuralink?

At the core of Neuralink’s platform is the N1 Implant — a wireless, rechargeable chip roughly the size of a quarter that sits flush against the skull, invisible from the outside. The device houses 1,024 electrodes on ultra-thin, flexible threads that detect and stimulate neural activity with extraordinary precision.[^12][^13]

The implant is placed by the R1 Robot, an automated surgical system that inserts electrode threads with a precision no human surgeon can replicate. In 2025, Neuralink unveiled an upgraded R1 with an electrode thread insertion time of just 1.5 seconds per thread, enhanced insertion depths over 50mm, compatibility with 99% of anatomical variations globally, and a 95% reduction in needle cartridge manufacturing costs.[^9]

The Device in Action

The N1 records neural signals — essentially “thoughts” — and translates them in real time into commands for external devices. Current trial participants have used their implants to:

• Play video games and control computer cursors at record-breaking speeds (4.6 bits per second on Day 1 for Patient 1)[^13]

• Browse the internet and post on social media using thoughts alone[^10]

• Use CAD software and 3D design applications[^14][^15]

• Control robotic arms via the CONVOY trial[^9]

Clinical Achievements — The Proof Is In the Patients

PRIME Study (U.S. — Paralysis)

The PRIME Study (NCT06429735) is Neuralink’s first-in-human trial evaluating the N1 Implant in patients with tetraparesis or tetraplegia due to ALS or spinal cord injury. The trial began in January 2024 with the first human implant at Barrow Neurological Institute in Phoenix, Arizona.[^7][^16]

Global Expansion in 2025

2025 was the defining year for Neuralink’s global credibility:

• United Kingdom: Partnership with University College London Hospitals and Newcastle Hospitals; first UK participant Paul controlled a computer with thoughts within hours of surgery[^17][^9]

• UAE: UAE-PRIME study launched at Cleveland Clinic Abu Dhabi in partnership with the Department of Health Abu Dhabi — Neuralink’s first Middle East trial[^17][^9]

• Canada: First non-U.S. procedures completed at Toronto’s University Health Network, implanting two patients with cervical spinal cord injuries[^9]

• Zero serious adverse device events reported across all trials[^11]

Participant Count Growth

FDA Designations — Triple Breakthrough Recognition

Neuralink has received three separate FDA Breakthrough Device Designations — a remarkable regulatory track record that signals official recognition of transformative medical potential:

1. PRIME / Motor Control (2023): Investigational Device Exemption granted, enabling first human trial for paralysis patients[^7]

2. Blindsight / Vision Restoration (September 2024): FDA Breakthrough Device Designation granted for the Blindsight implant — designed to restore vision by directly stimulating the visual cortex, bypassing damaged eyes and optic nerves entirely. Musk has stated this will eventually “exceed normal human vision”[^19][^20][^21][^22]

3. Speech Restoration (May 2025): FDA Breakthrough Device Designation granted for communication restoration covering ALS, stroke, spinal cord injury, cerebral palsy, multiple sclerosis, and other neurological conditions. Each Breakthrough Designation provides Neuralink with priority FDA review, expedited development pathways, and direct access to FDA experts — dramatically accelerating the commercial timeline.

Secondary Market: Where the Shares Are Trading

Neuralink is a private company — meaning access to its shares is restricted to sophisticated investors through primary funding rounds and secondary market transactions. Here is how the valuation and share price have moved over time:

Secondary market share prices on platforms like Nasdaq Private Market have risen approximately +243% to $96.66 as of February 2026. This reflects the private market’s growing appetite for BCI exposure ahead of a potential IPO.[^27]

The AMP Growth Collective 2 Opportunity

LPs of the AMP Growth Collective 2 have access to Neuralink at $53 per share — representing a substantial and dramatic discount compared to where secondary shares are currently trading on the open private market. With secondary prices reflected near $96+ and the company’s latest implied valuation approaching $14.87B, the $53 entry point provides a meaningful built-in margin of safety and significant upside optionality. This is the type of entry that institutional funds pay premiums to access — and it is available to AMP Growth Collective 2 LPs at a fraction of current market secondary pricing.

Short-Term Catalysts (2026 Outlook)

The next 12-18 months are loaded with potential catalysts that could meaningfully accelerate Neuralink’s valuation:

1. High-Volume Production & Automated Surgery
Elon Musk has publicly stated that Neuralink will move to “high-volume production” of brain implants and transition to a “streamlined, almost entirely automated surgical procedure” in 2026. This is the shift from artisanal neurosurgery to an industrial medical device — the moment the company scales.[^18][^28]

2. Next-Generation Implant
Musk announced that a next-generation brain implant with three times the current capabilities is expected to be ready in 2026. Greater electrode density means more precise control, higher-fidelity signal capture, and expanded therapeutic applications.[^10]

3. CONVOY Trial Results (Robotic Arm Control)
The CONVOY trial — testing BCI-controlled robotic arms in PRIME study participants — is actively enrolling and generating data. Positive outcomes here would represent a massive leap for commercial and rehabilitation applications.[^15][^9]

4. Blindsight Human Trial Launch
Following its FDA Breakthrough Designation, Blindsight is on track for its first human clinical trials. Successful early data in vision restoration would be a global headline event.[^21]

5. Speech Restoration Progress
With a fresh Breakthrough Designation from May 2025, Neuralink is expected to advance its speech restoration trial enrollment, targeting millions of patients with ALS, stroke, and spinal cord injuries.[^24]

6. Regulatory Expansion
Progress toward FDA premarket approvals across motor, speech, and vision platforms would represent commercial readiness milestones and likely trigger significant secondary market repricing.[^17]

Long-Term Possibilities — The Exponential Case

This is where G.L.A. Invest’s conviction runs deepest. The near-term applications in paralysis, blindness, and speech are multi-billion-dollar markets on their own. But Neuralink’s long-term ceiling is difficult to quantify — because it is nothing less than the expansion of human capability itself.

Addressable Markets — Layered and Expanding

The global BCI market is projected to grow from $1.79 billion in 2023 to $7.4 billion by 2033. However, this projection likely understates the scenario where Neuralink achieves consumer-grade commercial approval — a milestone that would open an entirely different order-of-magnitude market.[^29]

The 1 Million Patient Vision

Elon Musk has projected that Neuralink’s BCI technology could augment one million individuals by 2030. At even a modest recurring device/service revenue per patient, this represents annual revenues measured in the billions — without accounting for any cognitive enhancement or consumer market penetration.[^14]

Long-Term Technology Vision

Neuralink’s long-term roadmap includes capabilities that extend far beyond today’s clinical trials:

• Enhanced vision: Infrared, ultraviolet, and radar-like sensory perception[^30]

• Memory restoration and augmentation: Targeting Alzheimer’s and TBI

• Direct brain-to-brain and brain-to-AI communication

• Fully bidirectional neural interface: Not just reading thoughts — writing information back to the brain

These are not science fiction timelines — they are the stated roadmap of a company that has already implanted 21 human patients with zero serious adverse events, secured three FDA Breakthrough Designations, raised $1.85 billion in primary capital, and counts ARK Invest, Sequoia Capital, Founders Fund, Lightspeed, and Thrive Capital among its investors.[^3][^4][^8][^11][^23][^19][^7]

Competitive Positioning

Neuralink’s primary competitors in invasive BCI include Synchron (acquired by Bezos), Blackrock Neurotech, and academic spin-offs. However, Neuralink’s integrated approach — combining its own implant hardware, proprietary surgical robot, and software stack — creates a moat that competitors cannot easily replicate. No other company is pursuing all three of Neuralink’s current clinical indications (motor, speech, vision) simultaneously with active FDA designations.[^23][^7]

The combination of Elon Musk’s capital allocation expertise, his regulatory access in the current political climate, and a best-in-class technical team positions Neuralink as the likely category-defining player in the BCI space — analogous to what Tesla was to EVs in 2013-2015.

Risks to Consider

G.L.A. Invest maintains its commitment to transparent, honest research. No investment is without risk, and Neuralink is no exception:

• Regulatory Risk: Despite Breakthrough Designations, FDA full commercial approval for any indication is still years away

• Clinical Risk: Adverse events in future patients could slow trials or trigger regulatory scrutiny

• Technical Risk: Long-term electrode performance and device longevity in brain tissue remains under study

• Timeline Risk: Elon Musk’s stated timelines have historically been optimistic — delays are possible

• Liquidity Risk: As a private company, there is no guaranteed exit timeline; IPO timing is unknown[^31]

• Ethical / Social Risk: Public perception of brain implants and data privacy concerns could affect adoption rates

These risks are real — but they are the same risks that existed in every transformative technology at this stage. Tesla faced existential risk in 2013. SpaceX nearly failed in 2008. The investors who held through the uncertainty were rewarded with generational returns.

G.L.A. Invest View — Long-Term Conviction

The following reflects the personal investment belief of G.L.A. Invest Research.

It is our firm belief that Neuralink will generate insane returns for long-term investors. This is not hyperbole — it is a thesis grounded in first principles:

1. The technology works. We have 21 human patients as proof, with zero serious adverse events[^11]

2. The regulatory path is open. Three FDA Breakthrough Designations is an extraordinary track record for a company this young[^19][^7][^23]

3. The market is essentially unlimited. From medical devices to cognitive enhancement to human-AI integration, Neuralink is building the infrastructure for how humans interact with technology forever

4. The entry point is exceptional. At $53 for AMP Growth Collective 2 LPs, you are entering below the last primary round price and dramatically below secondary market trading prices

5. The founder effect is real. Elon Musk has built and scaled Tesla, SpaceX, and xAI. His pattern recognition, capital access, and regulatory relationships give Neuralink structural advantages no other BCI company possesses

The brain-computer interface space will produce the most valuable medical technology company in history. We believe that company is Neuralink — and the window to own it at this price is closing.

G.L.A. INVEST RESEARCH | Private Market Spotlight
© 2026 G.L.A. Invest. This document is for informational purposes only and does not constitute financial advice. Private market investments are illiquid, high-risk, and suitable only for accredited investors. Past performance is not indicative of future results. Always conduct your own due diligence.

References

1. Neuralink – Wikipedia – It was founded by Elon Musk and a team of eight scientists and engineers. … Neuralink was launched…

2. Neuralink Business Breakdown & Founding Story – Contrary Research – A report from Contrary Research. Discover Neuralink’s founding story, product, business model, and a…

3. Neuralink Stock: $9B Valuation — Is It a Buy? | TSG Invest – As of 2026, Neuralink has not announced specific IPO plans. The company completed a $650 million Ser…

4. Neuralink valuation, funding & news – Sacra – This followed a $600M raise in May 2025 at a $9.6 billion valuation, a $43 million raise in November…

5. Mind Over Machine: Neuralink’s History and Milestones – Neuralink was co-founded by Elon Musk and seven other engineers and scientists in 2016. Musk’s inten…

6. How Much Did Neuralink Raise? Funding & Key Investors – TexAu – 1. Seed Round · $1.62 M · Date: October 2010 ; 2. · $27 M · Date: August 2017 ; 3. · $39.3 M · Date:…

7. Neuralink wins FDA breakthrough tag for speech restoration – Neuralink shared limited details but did confirm that the treatment designation includes patients af…

8. Musk’s Neuralink raises $650 million in latest funding as … – Reuters – Elon Musk’s Neuralink said on Monday that it had raised $650 million in its latest funding round as …

9. Received FDA Breakthrough Device Designation for its speech … – NEURALINK 2025: – Received FDA Breakthrough Device Designation for its speech restoration technology…

10. Neuralink Expands Human Trials to 21 Participants as Musk … – Neuralink has expanded its human clinical trials to 21 participants worldwide, nearly doubling from …

11. Elon Musk’s Neuralink says it has 21 participants enrolled in trials – Neuralink began human trials of its brain implant in 2024 after addressing safety concerns raised by…

12. Neuralink Successfully Completes Goal of 20 Implants by 2026 – Neuralink hits 7 brain implants done in the UK, 20 globally, boosting Elon Musk’s BCI revolution for…

13. Neuralink in 2026: What the Human Patients Can Actually Do – 21 patients implanted. 10 hours of daily use. Thread retraction fixed. Here’s what Neuralink’s brain…

14. Neuralink stock update, December 2024 – IPO CLUB – Neuralink has received approval for a feasibility study involving its implant and a robotic arm. Thi…

15. Neuralink wins FDA breakthrough tag for speech restoration – Neuralink wins FDA breakthrough tag for speech restoration. Neuralink is currently conducting the fi…

16. PRIME Study Site Announcement – Barrow Neurological Institute – The first participant in Neuralink’s PRIME Study recently demonstrated the ability to use brain acti…

17. Neuralink’s Milestones in 2025 and Its Promising Future in 2026 – Neuralink expanded its clinical reach beyond the United States in 2025. The company launched its fir…

18. Elon Musk plans ‘high-volume production’ of Neuralink brain chips … – Elon Musk said that Neuralink implants will move to an “almost entirely automated surgical procedure…

19. Could the Blind See Again? Neuralink’s Blindsight Clears FDA Hurdle – Neuralink’s Blindsight implant receives FDA breakthrough designation, aiming to restore vision for i…

20. Neuralink’s Blindsight Implant Receives FDA Breakthrough Device … – The Blindsight implant uses a brain chip interface to process and transmit neural signals from the v…

21. Neuralink’s Blindsight Receives US FDA’s Breakthrough Device … – Blindsight, a brain-computer interface implant designed to help restore blindness, has been granted …

22. Musk’s Neuralink gets FDA’s breakthrough device tag for ‘Blindsight … – Elon Musk’s brain-chip startup Neuralink said on Tuesday its experimental implant aimed at restoring…

23. FDA Grants Breakthrough Status to Neuralink’s Speech-Restoring … – This designation applies to Neuralink’s device, which is designed to restore communication for indiv…

24. Neuralink’s speech restoration device gets FDA’s ‘breakthrough’ tag – Neuralink has received the US Food and Drug Administration’s “breakthrough” tag for its device to re…

25. Invest and Sell Neuralink Stock – Forge Global – Funding round and deals details ; 06/02/2025, Series E ; Price Per Share. $49.09. Shares Outstanding…

26. Neuralink (NEUR.PVT) Valuation, History & News – Yahoo Finance – 450.36% · Estimated Valuation 14.87B · Latest Funding Date Jun 2, 2025 · Total Amount Raised 1.34B ·…

27. Sell or Invest in Neuralink Stock Pre-IPO – Nasdaq Private Market – Neuralink Stock Price Chart. Neuralink Stock Price Per Share. $96.66 +$68.48 (+243.01%). Updated Feb…

28. Neuralink plans ‘high-volume’ brain implant production by 2026 … – Elon Musk’s brain implant company Neuralink will start “high-volume production” of brain-computer in…

29. Brain Computer Interface Market To Hit 7.4 Billion By 2033 – The Global Brain Computer Interface Market size is expected to be worth around USD 7419.0 Million by…

30. Neuralink Aims for Mainstream Use by 2026 with Brain Implant … – Future Vision Neuralink’s long-term goal is to enhance sight, enabling capabilities like infrared, u…

31. Neuralink IPO: Investment Opportunities & Pre-IPO Valuations – Forge – The Neuralink IPO price does not exist at this time, as Neuralink is still a private company and has…